Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis.

ABSTRACT:

Background

Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.

Objective

The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.

Methods

We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administrati

SUBMITTER: Daniels K 

PROVIDER: S-EPMC7313157 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature